Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

NCT03909334 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

160

Enrollment

OTHER

Sponsor class

Conditions

Non Small Cell Lung Cancer
EGFR Gene Mutation
Advanced Cancer
Metastatic Cancer

Interventions

DRUG: Osimertinib
DRUG: Ramucirumab

Sponsor

Xiuning Le

Collaborators

[object Object]
[object Object]